Get started
Author

Charalampos Charalampous

Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
2024 · Charalampos Charalampous, Utkarsh Goel, et al. · Clinical Lymphoma Myeloma & Leukemia · 14
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression
2024 · Charalampos Charalampous, Kimberley Doucette, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
Retreatment of multiple myeloma with previously refractory drugs
2024 · Utkarsh Goel, Charalampos Charalampous, et al. · Blood Advances · 2
PDF
Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)
2024 · Efstathios Kastritis, Eirini Katodritou, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2
Immune Checkpoint Inhibitors and Pericardial Disease: A Systematic Review
2024 · Sarah E. Mudra, Danny L Rayes, et al. · Research Square · 1
PDF
Comparison of Patient-Reported Peripheral Neuropathy Among Patients Treated With Elranatamab Versus Real-World Clinical Practice in Triple-Class Refractory Multiple Myeloma
2025 · Charalampos Charalampous, Ricardo Parrondo, et al. · JCO oncology advances.
PDF
Prognostic cut-off values of neutrofil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for COVID-19: a case-control retrospective single-center study
2024 · Amalia Papanikolopoulou, Eftychia Eirini Maria Gourdoupari, et al. · Journal of Global Antimicrobial Resistance
Radiomics-Based Biomarkers for Risk Stratification in Newly Diagnosed Multiple Myeloma
2024 · Jacob T Shreve, Michael D Howe, et al. · Blood
P-261 Comparison of different cutoffs of time from last drug exposure to disease progression for defining drug refractoriness in multiple myeloma
2023 · Utkarsh Goel, Charalampos Charalampous, et al. · Clinical Lymphoma Myeloma & Leukemia
P-262 Retreatment with previously refractory drugs in multiple myeloma
2023 · Utkarsh Goel, Charalampos Charalampous, et al. · Clinical Lymphoma Myeloma & Leukemia
P-281 Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory MM
2023 · Charalampos Charalampous, Utkarsh Goel, et al. · Clinical Lymphoma Myeloma & Leukemia
P-093 Solitary plasmacytoma: single institution experience and systematic review and meta-analysis of clinical outcomes
2023 · Charalampos Charalampous, Jean-Sebastien Claveau, et al. · Clinical Lymphoma Myeloma & Leukemia
P885: Solitary Plasmacytoma: Single Institution Experience and Systematic Review and Meta-analysis of Clinical Outcomes
2023 · Charalampos Charalampous, Jean-Sebastien Claveau, et al. · HemaSphere
P-126: Thrombosis in multiple myeloma – risk estimation by induction regimen and association with overall survival
2022 · Charalampos Charalampous, Utkarsh Goel, et al. · Clinical Lymphoma Myeloma & Leukemia
P-246: Impact of defining refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
2022 · Utkarsh Goel, Charalampos Charalampous, et al. · Clinical Lymphoma Myeloma & Leukemia
P-208: Association of thrombocytopenia with disease burden, high-risk cytogenetics, and survival in newly diagnosed multiple myeloma patients
2022 · Charalampos Charalampous, Utkarsh Goel, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
P-211: Changes in serum alkaline phosphatase levels during induction therapy to predict outcomes in patients with newly diagnosed multiple myeloma
2022 · Utkarsh Goel, Charalampos Charalampous, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 17
Citation count: 23
H-index: 2
I10-index: 1
Year
Topic
Type